Russia may face a shortage of some anti-cancer drugs for children, which is mainly due to the suspension of their supplies to the local market by local producers and importers, reports The Pharma Letter’s local correspondent. 23 March 2021
Californian aging specialist CohBar is using mitochondrial science to treat diseases, but chief executive Steven Engle doesn’t rule out offering a “cure for ageing” at some point. 23 March 2021
Russian Deputy Prime Minister Tatyana Golikova – a state official also responsible for the development of pharmaceutical and healthcare sector in the Russian government - has instructed the national government to speed the procedure for registration of new drugs in Russia and to provide additional preferences to domestic drugmakers during public procurements, according to recent statements by the state press-service and some local media, reports The Pharma Letter’s local correspondent. 23 March 2021
There has never been a better time to raise money for companies in the life sciences sector, according to Ben Long, partner at UK-headquartered private equity firm Inflexion. 23 March 2021
China has been relying on daily human growth hormone (HGH) injections to treat growth hormone deficiency (GHD), but this is likely to change, if not soon. 19 March 2021
A new strategy for the development of the domestic pharmaceutical sector until 2030 may soon be approved by the Russian government, according to recent statements some senior state officials and local media, reports The Pharma Letter’s local correspondent. 16 March 2021
As India's Biocon Biologics partners pharma giants Novartis and Pfizer to enhance access to life-saving cancer drugs for patients, especially in Sub-Saharan and Asian regions, several Indian drug majors are ponying up to ensure easy access to top cancer drugs, reports The Pharma Letter’s India correspondent. 15 March 2021
Catherine Penny, partner, and Laura Beagrie, professional support lawyer, Stevens & Bolton, consider an important issue brought to light by the scramble for coronavirus vaccines. 12 March 2021
For over two decades, the US Food and Drug Administration (FDA) has encouraged the incorporation of patient perspectives into drug development. A major component of the patient perspective is a drug’s effect on Quality of Life (QoL) – a concept that has always been a heterogeneous entity that lacks clear definition. 10 March 2021
The Russian pharmaceutical industry remains heavily dependent on imports of active pharmaceutical ingredients (APIs), despite efforts that have been made by the state to reduce import dependence in recent years, according to recent statements by representatives of some leading Russian pharmaceutical producers and analysts, reports The Pharma Letter’s local correspondent. 8 March 2021
Patrick Delavault, executive VP, scientific & medical affairs, LFB Biopharmaceuticals, provides an Expert View on how the pandemic has led to a focus on an important medicinal option for patients. 5 March 2021
Russian drugmaker Geropharm plans to become one of the leading players in the domestic insulins market within the next several years, with the possible launch of a biosimilar of ultra-long-acting insulin, produced by the Danish diabetes care giant Novo Nordisk, as well as a further expansion of its portfolio. 2 March 2021
An objective to attain self-reliance and reduce import dependence in India's pharmaceutical sector has resulted in the India government clearing 19 applications in a rapid-fire way with a committed investment of $628.84 million under its ambitious production linked incentive (PLI) scheme for the promotion of domestic manufacturing of critical key drug intermediates and active pharmaceutical ingredients (APIs), reports The Pharma Letter’s India correspondent. 1 March 2021
“Companies are borderless,” said Mark Duxon, chief executive of Transpharmation, a contract research organization (CRO) that has now added a Polish site to its UK and Irish facilities. 26 February 2021
Ambreen Farook, senior director, alliance management and program lead at Halozyme Therapeutics, provides an Expert View on the dos and don'ts of biopharmaceutical industry partnerships. 23 February 2021
Russia needs a total overhaul of its patent regulation system with regard to pharmaceuticals, with the aim to ensure access for the local population to cheaper drugs, according to recent statements by local pharma analysts and some domestic media, reports The Pharma Letter’s local correspondent. 23 February 2021
Sunday February 28 is Rare Disease Day – a time to review the current orphan drug landscape and the opportunities and challenges presented to the pharmaceutical industry. 22 February 2021
The recent merger of Mylan and Upjohn was one of the biggest in healthcare. But in their rebirth as Viatris (Nasdaq: VTRS), a lesson about the future of the industry may be in rediscovering its humanity, writes Christina Falzano, managing director, Conran Design Group, in an Expert View piece. 19 February 2021
Recent years have seen a growing number of Chinese biotechs doing their clinical studies outside China, reports The Pharma Letter’s local correspondent Wang Fangqing. 17 February 2021
In what is being considered a major fillip to the nation's biotechnology sector, the Indian government has decided to focus on product development commercialization biotech ecosystem in smaller tier-2 and tier-3 towns. A healthy engagement with biotech start-ups is being encouraged across the country, with an aim to take the industry to $150 billion by 2025, reports The Pharma Letter’s India correspondent. 17 February 2021
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024